Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00350181 · ClinicalTrials.gov registry record · Phase 2
Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT00350181: Completed Phase 2 study, sponsored by Stanford University.
NCT00350181 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00350181, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
GVHD prophylaxis of sirolimus and mycophenolate mofetil for patients undergoing matched related allogeneic transplant for acute and chronic leukemia, MDS, high risk NHL and HL
Interventions
- DRUG Sirolimus
- DRUG BCNU
- DRUG MMF
- DRUG CY
- DRUG VP-16
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2006-08 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00350181
The ClinicalTrials.gov registry entry for NCT00350181 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Sirolimus is the first listed.
NCT00350181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00350181 about?
NCT00350181 is a clinical study titled "Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT". GVHD prophylaxis of sirolimus and mycophenolate mofetil for patients undergoing matched related allogeneic transplant for acute and chronic leukemia, MDS, high risk NHL and HL
What is the current status of trial NCT00350181?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2006-08. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00350181?
The interventions under investigation include: Sirolimus (DRUG), BCNU (DRUG), MMF (DRUG), CY (DRUG), VP-16 (DRUG).
Who is sponsoring clinical trial NCT00350181?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.